PFS | OS | |||
---|---|---|---|---|
HR [95% CI] | P | HR [95% CI] | P | |
Age >60 years | 2.85 [1.19, 6.86] | 0.02 | 3.70 [1.22, 11.22] | 0.02 |
Ann Arbor stage IIIE-IVE | 4.92 [1.67, 14.52] | 0.004 | 6.41 [1.43, 28.59] | 0.01 |
LDH above normal | 2.18 [0.89, 5.33] | 0.09 | 2.29 [0.72, 7.26] | 0.16 |
ECOG >1 | 3.34 [1.45, 7.70] | 0.005 | 4.27 [1.54, 11.83] | 0.005 |
No. of extranodal sites | ||||
> 1 > 2 > 3 | 1.24 [0.50, 3.05] 2.64 [1.09, 6.36] 5.69 [1.99, 16.31] | 0.64 0.03 0.001 | 1.11 [0.38, 3.27] 2.56 [0.87, 7.51] 5.91 [1.79, 19.53] | 0.85 0.09 0.004 |
hypercalcemia | 4.69 [1.57, 14.03] | 0.006 | 7.52 [2.34, 24.12] | 0.0007 |
AP above normal | 0.88 [0.35, 2.16] | 0.77 | 0.71 [0.22, 2.24] | 0.56 |
Multifocal bone lesions | 1.10 [0.48, 2.52] | 0.83 | 1.23 [0.44, 3.46] | 0.69 |
Rituximab | 0.76 [0.29, 2.00] | 0.58 | 1.12 [0.30, 4.14] | 0.87 |
Intensified chemotherapy | 0.44 [0.16, 1.18] | 0.10 | 0.44 [0.12, 1.57] | 0.21 |
Radiotherapy | 0.55 [0.20, 1.47] | 0.23 | 0.09 [0.01, 0.72] | 0.02 |